First Mesothelioma Patient Treated with Tazemetostat in Global Phase 2 Trial
News
Epizyme announced that researches have initiated treatment of a first patient in the Phase 2 clinical trial of its first-in-class EZH2 inhibitor, tazemetostat, in adults with malignant mesothelioma. EZH2 is an enzyme that induces a type of ... Read more